Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort.

Publisher: Munksgaard Country of Publication: Denmark NLM ID: 9301549 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0625 (Electronic) Linking ISSN: 09066705 NLM ISO Abbreviation: Exp Dermatol Subsets: MEDLINE

Original Publication: Copenhagen : Munksgaard, c1992-

Genes, erbB-1* ; Genes, ras* ; Mutation*; Carcinoma, Squamous Cell/*genetics ; Skin Neoplasms/*genetics; Adult ; Aged ; Base Sequence ; Cohort Studies ; DNA Mutational Analysis ; DNA Primers/genetics ; Female ; Germany ; Humans ; Male ; Middle Aged

Epidermal growth factor receptor (EGFR) is highly expressed in squamous cell carcinoma (SCC). The response of patients with lung cancer to EGFR inhibitors is significantly associated with the presence of EGFR mutations. Although these drugs have already been used for the treatment of advanced cutaneous SCC, the knowledge about EGFR mutations in this cancer is limited to one previous study in the US population. We analysed the presence of EGFR and concomitant HRAS mutations in a German cohort of 31 patients with cutaneous SCC by direct sequencing of EGFR and SNaPshot analysis of concomitant RAS mutations. We found a low prevalence of EGFR mutations (1/31; 3%) and HRAS mutations (1/31; 3%). The detected P741L EGFR mutation was proven to be somatic. Our results indicate that both EGFR and HRAS mutations are rare events in the carcinogenesis of cutaneous SCC, and therefore, only a small subgroup of patients will benefit from the screening for EGFR mutations in the run-up to targeted therapies with EGFR inhibitors.
(© 2011 John Wiley & Sons A/S.)

0 (DNA Primers)

Date Created: 20110721 Date Completed: 20120116 Latest Revision: 20110920

20221213

10.1111/j.1600-0625.2011.01334.x

21771097